Why Is ASCENDIS PHARMA A/S (ASND) Stock Down Today?
By the Top Tier Newswire AI Desk · September 16, 2026 at 12:10 AM ET · reviewed against 13 wire stories
ASCENDIS PHARMA A/S (ASND) is down -9.49% in the latest session. Our newswire has captured 13 stories on ASND across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ASND stock is down today
Ascendis Pharma A/S (ASND) fell 9.49% to $239.77 in afternoon trading on September 15, 2026. The decline followed a downgrade from Raymond James, which cut the stock from Strong Buy to Outperform. The move came amid a broader sell-off in the sector and uncertainty around the company's strategic direction following the termination of its collaboration with Novo Nordisk.
What Happened
Raymond James downgraded Ascendis Pharma stock to Outperform from Strong Buy, citing a shift in partnership dynamics. This downgrade occurred as the company presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The stock had previously regained rights to its weight-loss technology after the Novo Nordisk collaboration ended in November 2024. Despite announcing a $400 million share repurchase program, the stock continued to decline. The Fly reported the stock down 12.1% and 12.8% at different points during the session, reflecting heightened volatility.
What The Data Shows
Over the last eight trading sessions, the stock has fallen 13.8%, from $268.17 to $231.13. On September 15, it printed 20 fresh 52-week lows. Recent insider transactions include a sale by Mads Bodenhoff, SVP and PAO, on September 8, and a purchase by Jean Jacques Bienaime, a director, on August 14. Over the last 90 days, insiders have bought $493,000 worth of shares and sold $811,000 worth. The stock is currently trading within its 52-week range of $186.05 to $282.15.
What To Watch
Investors should monitor the company's next earnings report and any further analyst actions. The stock's performance may also be influenced by broader market trends, particularly in the healthcare sector.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 13 stories · 58/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
11h agoSeeking AlphaBULLISH 56Product/PR
Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsJan Mikkelsen -...
16h agoThe FlyBEARISH 38Earnings
Ascendis Pharma falls -12.8%
18h agoThe FlyBEARISH 38Earnings
Ascendis Pharma falls -12.1%
23h agoThe FlyBEARISH 42Analyst
Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgrades Ascendis Pharma stock rating on partnership shift
Raymond James downgrades Ascendis Pharma stock rating on partnership shift
1d agoSeeking AlphaBULLISH 71General
Ascendis Pharma sets $400M stock buyback plan
Ascendis Pharma (ASND) authorizes a $400M share repurchase program, flexible and adjustable anytime.
1d agoMorningstarBULLISH 67General
Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis.
1d agoMarketWatchBULLISH 67General
Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →